Synthetic single domain antibody libraries and a binder selection cascade encompassing ribosome and phage display enable the selection of conformation-specific binders against previously intractable membrane proteins within three weeks.

Llama-derived single-domain antibodies, formatted as bispecific antibodies with human Fc domains, reduce and prevent bunyavirus-induced morbidity and mortality in mice upon prophylactic and therapeutic administration.

A fully synthetic library of humanized single domain antibodies yields in vitro high affinity antibodies usable in cell biology and translational projects.

High-affinity nanobodies targeting the SARS-CoV-2 spike protein demonstrate sustained effectiveness against current and emerging variants, offering a promising avenue for treatment.

Potent and low-cost Nanosota-1 drug candidates block SARS-CoV-2 infections in vitro and in animal models and act preventively and therapeutically.

HIV escapes human immune pressure through a single mutation in V2 domain of envelope protein leading to emergence of mutant-specific broadly reactive antibodies, a phenomenon recapitulated in combinatorial vaccine design.

A large repertoire of nanobodies that target discrete regions of SARS-CoV-2 spike shows effective neutralization against variants of concern with many pairwise combinations resistant to escape and demonstrating synergistic neutralization activities.

Protocols that greatly simplify the use of nanobodies in fluorescence imaging and affinity purification have been developed.

The antibody accessibility of the leptospiral surface protein, LigB, provides a guide for the rational design of improved recombinant chimeric vaccine antigens displayed on a single domain scaffold.

VAR2CSA, the leading candidate antigen for a placental malaria vaccine, displays epitopes targeted by naturally acquired broadly neutralizing antibodies of African multigravidae.